IL17A and chronic rhinosinusitis with nasal polyps: In this case report we describe two patients with a mixed Type II/Type III endotype CRSwNP who, after failing treatment with dupilumab, showed favourable treatment outcomes with secukinumab (anti‐IL‐17A antibody) treatment.